Market Overview

UPDATE: Credit Suisse Initiates AbbVie at Neutral on Humira Dependence

Share:
Related ABBV
Abbvie Announces Venetoclax Receives 3rd Breakthrough Therapy Designation from the FDA
AbbVie Announces NEJM Online Publication of Venetoclax Phase 1 Data in Relapsed/Refractory Chronic Lymphocytic Leukemia
Patent Case Against Gilead Re-Opened; Result Could Remove Share Overhang (Seeking Alpha)

Credit Suisse initiated AbbVie (NYSE: ABBV) with a Neutral rating and a $37.00 price target.

Credit Suisse noted, "AbbVie's cross-currents imply minimal stock movement from current price. Growth is modest with 2013-2020 sales and EPS CAGR at 2% and 3% respectively and only 20% revenue contribution from the pipeline by 2020. Humira contribution to ABBV is significant; contribution to sales '13-20 is at minimum 50%, and over 70% to profits. Positives: ~9% free cash flow yield, 4.3% dividend yield, 11.9x P/E (pharma 2013 average 13.9x), options on elagolix, ABT-199 for lymphoma & business development (BD). Negatives: overdependence on Humira and long-term competitive threat from orals and biosimilars, HCV franchise expectations already realistic."

AbbVie closed at $75.39 on Wednesday.

Latest Ratings for ABBV

DateFirmActionFromTo
Apr 2016Societe GeneraleInitiates Coverage onSell
Mar 2016Deutsche BankInitiates Coverage onHold
Mar 2016Goldman SachsDowngradesConviction BuyBuy

View More Analyst Ratings for ABBV
View the Latest Analyst Ratings

Posted-In: Credit SuisseAnalyst Color Initiation Analyst Ratings

 

Related Articles (ABBV)

View Comments and Join the Discussion!